Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Identification of a T-cell population associated with outcomes in myeloma with t(4;14) translocation

Andreas Schmidt and Jonathan Scolnick • 11 Dec 2022
ASH 2022
Multiple Myeloma

Andreas Schmidt, PhD, Singleron Biotechnologies, Cologne, Germany, and Jonathan Scolnick, PhD, Singleron Biotechnologies, Singapore, Singapore, comment on the use of single-cell technologies in multiple myeloma, highlighting the results of a recent study that identified a T-cell population correlating with progression-free survival (PFS) in patients with multiple myeloma carrying translocation t(4;14). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Singleron Biotechnologies

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals